WMT — Walmart Inc.

The market is split: the August 20 Q2 FY27 print beat on revenue and adjusted EPS, but U.S. comps slowed to 2.6% (weakest in six years), Q3 EPS guidance of $0.62-$0.64 missed consensus, and Walmart is reinvesting tariff refunds into price rollbacks that compress near-term margins. The stock fell sharply into the low $100s, and while analysts maintain a consensus Buy, several firms trimmed price targets in response to the reset.

Revenue growth is stable but showing signs of deceleration: Q2 FY27 revenue grew 5.9% YoY to $187.94B, versus +7.3% in Q1 FY27, +5.6% in Q4 FY26, and +5.8% in Q3 FY26. Operating margin expanded to 5.0% in Q2 FY27 from 4.1% a year earlier, helped by tariff refunds and operating leverage, but reported diluted EPS fell to $0.80 from $0.88 because below-operating-line items offset the operating income gain. The real inflection is in the comp trajectory: U.S. same-store sales growth of 2.6% is a clear slowdown, with pharmacy regulation and more cautious consumer spending as the main brakes. This reads as a slowing defensive grower, not a broken business, but Q3 guidance suggests the margin pressure is far from over.

Still expensive relative to near-term growth, though less extreme after the pullback. As of 2026-08-27, TTM P/E is 37.1x versus the 5-year average of 35.0x, and the forward P/E is roughly 35.5x next-FY EPS of $2.889. Price-to-sales of 1.11x is also above the 5-year average of 0.90x, and the PEG of roughly 9x only makes sense if EPS growth reaccelerates well beyond the ~4% consensus. WMT is not the 40x+ story it was earlier in the year, but investors are still paying a premium multiple for defensive quality and high-margin mix rather than buying a bargain.

The market spent much of 2026 pricing Walmart as a defensive compounder; the Q3 guidance reset forced that premium down toward current earnings power. At $102.63, the stock is roughly pricing in flat near-term earnings growth and waiting for proof that the 11,000+ price rollbacks can reaccelerate U.S. traffic and comps. If Q3 FY27 shows stabilizing comps and only modest margin compression, this is probably near fair value with an attractive entry point; if the consumer weakens further, the multiple could compress toward the low-30s, implying $90 or lower.

As of 2026-08-27, RSI-14 was 31.8, just above oversold territory, and the price was -7.2% below the 20-day SMA, -8.6% below the 50-day SMA, and -13.5% below the 200-day SMA. That is a clear intermediate-term downtrend after the earnings gap, and the stock sits only about 7% above its 52-week low of $95.80. There is no confirmed bottom yet; a further push below RSI 30 or a reclaim of the 20-day moving average would be the first meaningful tactical improvement.

• Consumer health and trade-down behavior: higher-income households are trading down into Walmart, but lower average tickets show the broader consumer is still budget-constrained.
• Pharmacy pricing regulation: new rules clipped U.S. comps by roughly 80 basis points and could keep pressuring pharmacy margins.
• Tariff policy and refunds: tariff refunds provided a ~750bps operating income benefit in Q2, but reinvesting that into price rollbacks compresses forward margins.
• Interest rates and inflation: higher-for-longer rates weigh on discretionary spending and valuation multiples, though Walmart's staples-heavy mix is defensive.
• Supply chain and automation capex: elevated capex on automated distribution, e-commerce infrastructure, and drone delivery is a near-term FCF drag but a long-term margin lever.

• Q3 FY27 earnings in mid-November 2026: the key test of whether price rollbacks reaccelerate U.S. comps and whether Q3 guidance was conservatively set.
• Holiday season retail data: early Q4 sales will signal whether the American consumer is still spending and whether Walmart is gaining or losing share.
• Walmart Connect advertising, e-commerce, and Walmart+ membership growth: high-margin streams are the main path to beating the ~4% EPS growth consensus.
• Flipkart Big Billion Days timing: a ~100bps international Q3 headwind that later flips into an easier comparison for FY28.

• Same-store sales deceleration: 2.6% U.S. comp growth is the weakest in six years, and if price investments don't revive traffic, the growth narrative weakens further.
• Margin compression from price investments and tariff uncertainty: aggressive rollbacks are good for market share but bad for near-term operating margin.
• Valuation de-rating: at 37x TTM earnings, WMT has limited room for negative revisions; a multiple compress to 30x could put the stock near $85-$90.
• Competition from Amazon, Costco, and Target: all are investing in price, digital, and membership, which could pressure Walmart's recent share gains.
• Regulatory risk: further pharmacy or healthcare pricing reforms could shave more comps and margins.

Walmart is a high-quality defensive business with a credible structural shift toward higher-margin advertising, membership, and e-commerce revenue, but the stock still carries a premium valuation for only ~4% near-term EPS growth. The Q3 guidance reset and slowing comps make the near-term fundamental path less certain, so this is a 'great company, fair-to-rich price, wait for confirmation' situation rather than a clear bargain.

Applied roughly a 35x forward P/E multiple, consistent with Walmart's 5-year average P/E of 34.97, to the next-fiscal-year EPS estimate of $2.889. That yields $101.1, a slight discount to the current price, reflecting the rich valuation context, low near-term EPS growth, and a modest offset for Walmart's higher-margin mix shift.